Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Surgical complications and risk factors in elderly patients after kidney transplantation: A single-center retrospective study.

The French journal of urology·2026
Same author

Small extracellular vesicle-mediated transfer of HPV16 transcripts from Ca Ski cells increases proliferation of HPV-negative recipient cancer cells.

Cell communication and signaling : CCS·2026
Same author

Corrigendum to "Combination of CDX2H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer" [In European Journal of Cancer, Volume 172, 2022, Pages 221-230, ISSN 0959-8049].

European journal of cancer (Oxford, England : 1990)·2026
Same author

Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm: assessing spatial response and unraveling resistance mechanisms.

Haematologica·2026
Same author

Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective Study.

European urology oncology·2026
Same author

Dynamic DNA methylation changes during colorectal oncogenesis with insights from adenoma stages.

Scientific reports·2025

相关实验视频

Updated: Jul 11, 2026

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

14.7K

同时降低E-和A-FABP表达预测尿膀癌患者的生存率较差.

Inès Saizonou1, Isabelle Lascombe2, Franck Monnien1

  • 1CHU Besançon, Service Anatomie et Cytologie Pathologiques, 25000, Besançon, France.

Scientific reports
|July 4, 2024
PubMed
概括

在非肌肉侵入性膀癌 (NMIBC) 中评估表皮脂肪酸结合蛋白 (E-FABP) 揭示了其预后价值. 结合脂肪细胞-脂肪酸结合蛋白 (A-FABP) 的评估,E-FABP有助于分层泌尿道癌患者进行量身定制的治疗和随访.

更多相关视频

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:25

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

1.8K
Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
04:57

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

460

相关实验视频

Last Updated: Jul 11, 2026

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

14.7K
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:25

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

1.8K
Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
04:57

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

460

科学领域:

  • 在瘤学瘤学.
  • 分子病理学分子病理学
  • 尿癌研究 尿癌研究

背景情况:

  • 非肌肉侵入性膀癌 (NMIBC) 呈现出不可预测的临床过程,具有高复发和进展风险.
  • 以前的研究表明,脂肪细胞-脂肪酸结合蛋白 (A-FABP) 损失是NMIBC进展的预测因素.
  • 确定NMIBC进展的可靠生物标志物对于患者管理至关重要.

研究的目的:

  • 调查NMIBC中表达表皮-脂肪酸结合蛋白 (E-FABP) 的预后意义.
  • 探索E-FABP和A-FABP在尿路癌中的综合预后价值.
  • 为了优化治疗和随访策略,对患者进行分层.

主要方法:

  • 免疫组织化学被用来评估210个NMIBC瘤样本 (pTa-pT1) 中的E-FABP表达.
  • 进行了相关性分析,以将E-FABP表达与瘤等级,阶段,淋巴结转移和内脏转移联系起来.
  • 卡普兰-梅尔分析用于评估E-FABP表达与无复发生存 (RFS),无进展生存 (PFS) 和整体生存 (OS) 的关联.

主要成果:

  • 低E-FABP表达与高等级/阶段,淋巴结转移和内脏转移有显著的相关性 (p < 0.001).
  • 虽然低E-FABP表达不能预测RFS或PFS,但高E-FABP表达与较长的整体存活时间有关 (53.8个月与29.3个月,p = 0.029).
  • 观察到一种补偿关系:当A-FABP缺席时,检测到高E-FABP表达. 患有低E-FABP和负A-FABP的患者的生存率最差,而表达这两种标志物的患者的生存率更好.

结论:

  • 对A-FABP和E-FABP表达的综合评估为分层泌尿道癌患者提供了可靠的方法.
  • 这种结合生物标志物方法可以帮助优化NMIBC的治疗决策和后续方案.
  • E-FABP作为潜在的预后标志物,特别是当与A-FABP一起评估时,用于管理膀癌患者.